LOGIN  |  REGISTER

Senseonics (NYSEAMEX: SENS) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$0.54 0.02 3.79
Volume: 6,320,453
5-Day Change: -5.32%
YTD Change: -47.60%
Market Cap: US$285.060M

Latest News From Senseonics

September 14, 2023
Senseonics to Participate in the Gilmartin Group Emerging Growth Company Showcase
GERMANTOWN, Md. / Sep 14, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to... Read More
September 11, 2023
Senseonics Enters Into $50 Million Loan Facility With Hercules Capital
GERMANTOWN, Md. / Sep 11, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced it drew... Read More
August 10, 2023
Senseonics Reports Second Quarter 2023 Financial Results
GERMANTOWN, Md. / Aug 10, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the second... Read More
July 27, 2023
Senseonics Holdings Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
GERMANTOWN, Md. / Jul 27, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023. Management will hold a... Read More
July 5, 2023
Senseonics Announces Equity Grants To Employees Under Inducement Plan
GERMANTOWN, Md. / Jul 05, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide... Read More
June 26, 2023
Senseonics: New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
Eversense E3 system can provide accurate performance through 365-day period Superior glucose outcomes achieved with use of Eversense E3 CGM GERMANTOWN, Md. / Jun 26, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted... Read More
June 2, 2023
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
Coverage policy expands access to the over 45 million lives covered by the largest healthcare insurance company in the United States GERMANTOWN, Md. / Jun 02, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that... Read More
May 26, 2023
Senseonics to Participate in the Jefferies Healthcare Conference
GERMANTOWN, Md. / May 26, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY. Management is scheduled to present on Friday, June 9,... Read More
May 9, 2023
Senseonics Holdings Reports First Quarter 2023 Financial Results
GERMANTOWN, Md. / May 09, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the first... Read More
April 27, 2023
Senseonics Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
GERMANTOWN, Md. / Apr 27, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023. Management will hold a conference... Read More
April 24, 2023
Ascensia Diabetes Care Marks One-year Anniversary Of US Eversense E3 CGM Launch With Commercial Update And Innovation Outlook
PARSIPPANY, N.J. , April 24, 2023 /PRNewswire/ -- Ascensia Diabetes Care , a global diabetes care company, maker of the CONTOUR ® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense ® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense ® E3 in the U.S. with a commercial update and outlook on future innovation, as discussed in the recent... Read More
April 18, 2023
Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
GERMANTOWN, Md. / Apr 18, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR... Read More
April 5, 2023
Senseonics Announces Equity Grants To Employees Under Inducement Plan
GERMANTOWN, Md. / Apr 05, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide... Read More
March 15, 2023
Senseonics Reports Fourth Quarter and Full Year 2022 Financial Results
GERMANTOWN, Md. / Mar 15, 2023 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022. Recent Highlights & Accomplishments: Generated fourth quarter 2022... Read More
January 5, 2023
Senseonics Announces Equity Grants To Employees Under Inducement Plan
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On January 5, 2023, the Senseonics... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous